Hyperfine (HYPR) vs Outset Medical (OM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Outset Medical (OM) has outperformed Hyperfine (HYPR) over the past year, losing 34.5% versus a loss of 48.0%. Over five years, HYPR leads with a -94.5% price change compared with -99.6% for OM. Hyperfine is the larger company by market cap ($58.0 million vs $53.0 million), about 1.1 times the size.
Outset Medical converts more of its revenue into profit, with a net margin of -68.3% versus -262.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HYPR | OM |
|---|---|---|
| Share price | $0.5465 | $2.81 |
| Market cap | $57.96M | $53.03M |
| 1-day change | +4.27% | -3.44% |
| YTD return | -44.18% | -24.26% |
| 1-year return | -47.95% | -34.50% |
| 5-year return | -94.45% | -99.61% |
| EPS (TTM) | $-0.29 | $-3.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.56M | $119.48M |
| Revenue growth (YoY) | +5.22% | +5.09% |
| Net income (latest FY) | $-35.57M | $-81.65M |
| Gross margin | 49.79% | 39.13% |
| Operating margin | -273.43% | -55.83% |
| Net margin | -262.29% | -68.34% |
| 52-week high | $1.94 | $6.49 |
| 52-week low | $0.488 | $2.77 |
| Distance from 52-week high | -71.76% | -56.70% |
| Analyst consensus | none | buy |
| Avg. price target upside | +271.45% | +172.95% |
| Average volume | 760.76K | 140.40K |
| Shares outstanding | 90.99M | 18.87M |
| Employees | 102 | 310 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OM has outperformed HYPR by 13.5 percentage points over the past year.
- Outset Medical is more profitable, keeping -68.3 cents of every revenue dollar as net income versus -262.3 cents for Hyperfine.
About Hyperfine
HYPR stock →Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 102 employees
About Outset Medical
OM stock →Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 310 employees
HYPR vs OM FAQ
Which is bigger, Hyperfine or Outset Medical?
Hyperfine (HYPR) is larger, with a market capitalization of $57.96M compared with $53.03M for Outset Medical (OM).
Which stock has performed better over the past year, HYPR or OM?
OM returned -34.50% over the past 12 months, compared with -47.95% for HYPR (price return, excluding dividends). Past performance does not predict future results.
Are Hyperfine and Outset Medical in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.